BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32299093)

  • 1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
    Maia C; Puig N; Cedena MT; Goicoechea I; Valdes-Mas R; Vazquez I; Chillon MC; Aguirre P; Sarvide S; Gracia-Aznárez FJ; Alkorta G; Calasanz MJ; Garcia-Sanz R; Gonzalez M; Gutierrez NC; Martinez-Lopez J; Perez JJ; Merino J; Moreno C; Burgos L; Alignani D; Botta C; Prosper F; Matarraz S; Orfao A; Oriol A; Teruel AI; de Paz R; de Arriba F; Hernandez MT; Palomera L; Martinez R; Rosiñol L; Mateos MV; Lahuerta JJ; Blade J; San Miguel JF; Paiva B
    Blood; 2020 Jun; 135(26):2375-2387. PubMed ID: 32299093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
    Barlogie B; Tricot G; Haessler J; van Rhee F; Cottler-Fox M; Anaissie E; Waldron J; Pineda-Roman M; Thertulien R; Zangari M; Hollmig K; Mohiuddin A; Alsayed Y; Hoering A; Crowley J; Sawyer J
    Blood; 2008 Jan; 111(1):94-100. PubMed ID: 17895401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
    Martinez-Lopez J; Fernández-Redondo E; García-Sánz R; Montalbán MA; Martínez-Sánchez P; Pavia B; Mateos MV; Rosiñol L; Martín M; Ayala R; Martínez R; Blanchard MJ; Alegre A; Besalduch J; Bargay J; Hernandez MT; Sarasquete ME; Sanchez-Godoy P; Fernández M; Blade J; San Miguel JF; Lahuerta JJ;
    Br J Haematol; 2013 Dec; 163(5):581-9. PubMed ID: 24117042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
    Kyle RA
    Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
    Requirand G; Robert N; Boireau S; Vincent L; Seckinger A; Bouhya S; Ceballos P; Cartron G; Hose D; Klein B; Moreaux J
    Cytometry B Clin Cytom; 2019 May; 96(3):209-214. PubMed ID: 30417559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS-type molecular findings compared to CCUS without dysplasia.
    Jajosky AN; Sadri N; Meyerson HJ; Oduro KA; Kelkar A; Fitzgerald B; Tomlinson B; Moore EM; Beck RC
    Eur J Haematol; 2021 Apr; 106(4):500-507. PubMed ID: 33386622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
    Paiva B; Puig N; Cedena MT; Rosiñol L; Cordón L; Vidriales MB; Burgos L; Flores-Montero J; Sanoja-Flores L; Lopez-Anglada L; Maldonado R; de la Cruz J; Gutierrez NC; Calasanz MJ; Martin-Ramos ML; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Blanchard MJ; Rios R; Martin J; Martinez-Martinez R; Sureda A; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Van Dongen JJM; Orfao A; Mateos MV; Blade J; San-Miguel JF; Lahuerta JJ;
    J Clin Oncol; 2020 Mar; 38(8):784-792. PubMed ID: 31770060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
    Martínez-Climent JA; Comes AM; Vizcarra E; Benet I; Arbona C; Prósper F; Solano C; García Clavel B; Marugán I; Lluch A; García-Conde J
    Bone Marrow Transplant; 2000 Jun; 25(11):1203-8. PubMed ID: 10849534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
    Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
    Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Royle KL; O'Connor S; Cairns DA; Ashcroft AJ; Williams CD; Hockaday A; Cavenagh JD; Snowden JA; Ademokun D; Tholouli E; Andrews VE; Jenner M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Drayson MT; Brown JM; Morris TCM;
    Br J Haematol; 2019 May; 185(3):450-467. PubMed ID: 30729512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.
    Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta JJ; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín JL; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal MJ; Solano C; Leon A; Sánchez JJ; Martínez-Chamorro C; Fernández-Rañada JM
    Bone Marrow Transplant; 1998 Jan; 21(2):133-40. PubMed ID: 9489629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation.
    Sevilla J; Rodríguez A; Hernández-Maraver D; de Bustos G; Aguado J; Ojeda E; Arrieta R; Hernández-Navarro F
    Ann Hematol; 2002 Jan; 81(1):11-5. PubMed ID: 11807629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma.
    Govindarajan R; Jagannath S; Flick JT; Vesole DH; Sawyer J; Barlogie B; Tricot G
    Br J Haematol; 1996 Nov; 95(2):349-53. PubMed ID: 8904891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
    Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
    Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
    Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
    Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.
    Mouhieddine TH; Sperling AS; Redd R; Park J; Leventhal M; Gibson CJ; Manier S; Nassar AH; Capelletti M; Huynh D; Bustoros M; Sklavenitis-Pistofidis R; Tahri S; Hornburg K; Dumke H; Itani MM; Boehner CJ; Liu CJ; AlDubayan SH; Reardon B; Van Allen EM; Keats JJ; Stewart C; Mehr S; Auclair D; Schlossman RL; Munshi NC; Anderson KC; Steensma DP; Laubach JP; Richardson PG; Ritz J; Ebert BL; Soiffer RJ; Trippa L; Getz G; Neuberg DS; Ghobrial IM
    Nat Commun; 2020 Jun; 11(1):2996. PubMed ID: 32533060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation.
    Chitre S; Stölzel F; Cuthill K; Streetly M; Graham C; Dill C; Mohamedali A; Smith A; Schetelig J; Altmann H; Bornhäuser M; Mufti GJ
    Leukemia; 2018 Sep; 32(9):2020-2024. PubMed ID: 30026569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.